Reports Q2 revenue $18.6M vs. $14.8M last year. “We are pleased to report once again record quarterly revenues and pre-tax net income predominately from sales of QuantaFlo(R) for peripheral arterial disease testing,” said Doug Murphy-Chutorian, MD, chief executive officer of Semler Scientific. “We are encouraged by our results year to date and are highly focused on developing our business in heart dysfunction.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SMLR:
- Semler Scientific Reports Second Quarter and First Half of 2023 Financial Results
- SMLR Earnings this Week: How Will it Perform?
- Semler Scientific pullback presents buying opportunity, says Lake Street
- Semler Scientific to reduce headcount 30% by September 15
- Semler Scientific sees Q2 revenue the highest in history
